InvestorsHub Logo
Followers 155
Posts 2695
Boards Moderated 0
Alias Born 01/29/2004

Re: None

Friday, 09/24/2021 5:00:00 PM

Friday, September 24, 2021 5:00:00 PM

Post# of 473760
Another Anavex Clinical Research Week Has Passed

Of course, no announcements or data from any of the three on-going clinical trials that will ultimately demonstrate blarcamesine's safety and efficacy for a) girls with Rett syndrome (this is not sexist; boys who inherit the disease’s genetic anomalies die before birth), b) people suffering from Parkinson’s disease dementia, and finally, c) a statistically sufficient number of people with Alzheimer’s disease.

No results data yet that we can see. But those data are continuing to accumulate, nonetheless. None of the three clinical trials have been halted; patients continue to be dosed with blarcamesine, and the clinical results of the drug continue to be accurately and precisely assessed. When each of the clinical studies are complete, and their therapeutic result data points are properly crunched (with detailed statistical analyses) the information will be made public; to be seen and considered by one and all.

First, with profound consideration of the clinical results, will be both the blarcamesine patients and their families and care givers; revealing whether or not the drug will continue to be available.

Next will be both medical science and investment news writers. These “smart people” will have to interpret for the general public just what the blarcamesine results might mean; whether or not they hold any promise.

Lastly (but quite importantly) will be us; those of us who have taken and hold AVXL equity positions. What we’ve been expecting for these many years will, finally, start to become reality.

Until then, everyone must just wait. Biochemical processes can’t be hastened by external mental hopes or imaginations. Blarcamesine-activated sigma-1 receptor proteins will function at their own pace.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News